Table 5.
Predictors of atrial fibrillation recurrence during 12 months after electrical cardioversion
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR [CI 95%] | P | HR [CI 95%] | P | |
| Age, years | 1.003 (0.98–1.04) | 0.8 | ||
| Gender, male=1 | 0.92 (0.51–1.67) | 0.8 | ||
| AF history, years | 0.99 (0.93–1.07) | 0.9 | ||
| AF episode duration before CV, days | 1.001 (0.99–1.006) | 0.7 | ||
| Coronary artery disease | 0.90 (0.48–1.71) | 0.7 | ||
| Diabetes | 0.75 (0.39–1.41) | 0.4 | ||
| Chronic obstructive pulmonary disease | 1.18 (0.53–2.65) | 0.7 | ||
| Chronic kidney disease | 1.23 (0.68–2.24) | 0.5 | ||
| Left ventricular ejection fraction, % | 0.94 (0.89–0.99) | 0.03 | 0.93 (0.86–1.00) | 0.052 |
| Left atrial diameter, mm | 1.01 (0.94–1.09) | 0.7 | ||
| Left atrial emptying fraction <38% | 1.78 (0.97–3.27) | 0.06 | 2.36 (1.09–5.09) | 0.03 |
| NPT I, nmol/L | 1.02 (0.98–1.06) | 0.4 | ||
| NPT II, nmol/L | 1.03 (0.99–1.07) | 0.15 | 0.99 (0.93–1.06) | 0.8 |
| NPT III, nmol/L | 1.02 (0.98–1.07) | 0.3 | ||
| NPT III≥13.3 nmol/L | 2.81 (1.10–7.16) | 0.03 | 3.21(0.90–11.5) | 0.07 |
| IL-6 I, pg/mL | 0.98 (0.90–1.07) | 0.7 | ||
| IL-6 II, pg/mL | 1.05 (0.97–1.14) | 0.19 | 1.04 (0.95–1.13) | 0.4 |
| IL-6 III, pg/mL | 0.97 (0.84–1.12) | 0.7 | ||
| ACE/ARB | 0.82 (0.44–1.52) | 0.5 | ||
| Statin | 0.69 (0.33–1.44) | 0.3 | ||
ACEI - angiotensin-converting enzyme inhibitor; AF - atrial fibrillation; ARB - angiotensin II receptor blocker; CI - confidence interval; CV - electrical cardioversion; IL-6 - interleukin-6; NPT - neopterin; OR - odds ratio